Endoscopic ultrasound ablation plus immunotherapy for pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of endoscopic ultrasound-guided heat ablation (RFA) and the immunotherapy drug pembrolizumab for people with locally advanced or metastatic pancreatic cancer that cannot be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic cancer that is locally advanced (has spread to nearby tissues) or metastatic (has spread to other parts of the body) and cannot be removed by surgery.
- You have not received any prior chemotherapy or radiation for this cancer, except if you completed adjuvant therapy (after surgery) at least 3 months ago, or you have stable disease after 3 months of first-line chemotherapy.
- You are in good enough general health to carry out daily activities (ECOG performance status 0-2).
- You have normal blood cell counts and adequate kidney and liver function, as measured by blood tests.
- You do not have active autoimmune disease, HIV, active tuberculosis, or another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial is for people with pancreatic ductal adenocarcinoma (a type of pancreatic cancer) confirmed by biopsy. It tests a new treatment strategy after the cancer is diagnosed and considers people who haven’t had certain chemotherapy yet.
This early-phase trial is testing a new endoscopic (from inside the stomach) approach for pancreatic ductal adenocarcinoma that is locally advanced and cannot be removed with surgery. It may help some people who have already tried first chemotherapy and still have a tumor confined to the pancreas area (no spread).
This trial tests combining endoscopic ultrasound-guided radiofrequency ablation with FOLFIRINOX chemotherapy for people with advanced pancreatic cancer that hasn't spread to other organs. It aims to see if this approach is safe and effective.
This trial tests combining cryoablation (freezing tumors) with a dual-antibody drug (PD-1/CTLA-4) for people whose locally advanced pancreatic cancer has stopped responding to first-line chemotherapy (AG regimen). The goal is to see if this combination can help control the cancer.
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
This trial tests if adding radiation and an immunotherapy drug (serplulimab) to standard chemotherapy can help people with pancreatic cancer that has come back or spread. It is for those who haven't had prior treatment for advanced disease.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.